Ovarian carcinoma is a prevalent worldwide disease, with over 200,000 new cases diagnosed per year (1). The first-line chemotherapy for newly-diagnosed ovarian carcinoma is cisplatin, but despite high initial efficacy, the most common types of ovarian carcinomas frequently relapse into platinum-resistant forms and many demonstrate multi-drug resistance (1). The availability of cellular models that recapitulate both resistant and susceptible forms of the disease are essential to understanding drug resistance and advancing new options for treatment.OVCAR-4 is a high-grade serous ovarian adenocarcinoma cell line established from a patient refractory to cisplatin, and is resistant to multiple chemotherapeutic agents (2). OVCAR-4 cells are characterized by migration/invasion ability and are tumorigenic in nude mice (3). The OVCAR-4 cell line is homozygous for the Leu130Val mutation in TP53 (4) and expresses high levels of the cancer marker integrin αvβ3 (5). OVCAR-4 cells are recommended to be passaged at relatively high density (at least 13,000 cells/cm2). OVCAR-4 is one of the most representative cell lines for high-grade serous ovarian carcinoma and a highly relevant model for multidrug-resistant ovarian cancer.Source:OVCAR-4 was established from ascites from a 42-year-old patient with an ovarian tumor refractory to cisplatin treatment (2).References:1. Nat Rev Disease Primers 2016; 2: 16061. 2. Cancer Res 1997; 57: 850—856.3. Gynecol Oncol 2015;138(2): 372-377. 4. Mol Cancer Ther 2006; 5(11): 2606-2612.5. Bioorganic & Medicinal Chem 2018; 26: 2085-2091.，官网链接：https://www.sigmaaldrich.cn/product/mm/scc258 默克 科研、开发、生产。 作为生命科学行业的全球领先供应商，我们致力于为科研、生物技术开发和生产，以及制药药物疗法开发和生产提供各类解决方案和服务。

非质量问题不退不换